Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

Zhenqi Jiang,Yanying Li,Zhenni Wei,Bo Yuan,Yinjie Wang,Ozioma Udochukwu Akakuru,Yong Li,Juan Li,Aiguo Wu

DOI: https://doi.org/10.1016/j.bioactmat.2020.08.036

IF: 18.9

2021-03-01

Bioactive Materials

Abstract:Zeolitic Imidazole Frameworks (ZIFs) are widely applied in nanomedicine for their high drug loading, suitable pore size, pH-responsive drug release, and so on. However, fast drug release during circulation, unexpected toxicity to mice major organs, undesirable long-term accumulation in the lung and even death currently hinder their <i>in vivo</i> biomedical applications. Herein, we report an amorphous ZIF-8 (aZIF-8) with high loading of 5-Fu through pressure-induced amorphization. This nano-system avoids early drug release during circulation and provides tumor microenvironment-responsive drug release with improved <i>in vitro</i> cell viability, and survival rate in <i>in vivo</i> evaluations as compared to ZIF-8. Furthermore, aZIF-8 shows longer blood circulation and lower lung accumulation than ZIF-8 at same injected doses. Less drug release during circulation, longer blood circulation, and better biocompatibility of aZIF-8/5-Fu significantly improves its therapeutic efficacy in ECA-109 tumor-bearing mouse, and result in 100% survival rate over 50 days after treatment. Therefore, aZIF-8 with favorable biocompatibility and long blood circulation is expected to be a promising nano-system for efficacious cancer therapy <i>in vivo</i>.

engineering, biomedical,materials science, biomaterials

What problem does this paper attempt to address?

This paper aims to solve some key problems faced by ZIFs (zeolitic imidazolate frameworks) in biomedical applications. Specifically, the author attempts to prepare a new type of nano - system - aZIF - 8 (amorphous ZIF - 8) through the method of pressure - induced amorphization to improve several major defects of traditional ZIF - 8 in in - vivo applications:

1. **Rapid drug release**: During the blood circulation process, traditional ZIF - 8 will release drugs too quickly, which not only reduces the therapeutic effect but also may cause side effects.
2. **Unexpected toxicity**: ZIF - 8 has unexpected toxicity to the main organs of mice at high doses, limiting its clinical application.
3. **Long - term lung accumulation**: ZIF - 8 accumulates in the lungs for a long time in the body, which may cause adverse reactions and even lead to death.

To overcome these problems, the author designed a method to transform ZIF - 8 into an amorphous state (aZIF - 8) through high - pressure treatment. This new nano - system has the following advantages:

- **Reduce drug release during circulation**: The drug release rate of aZIF - 8 in blood circulation is significantly reduced, reducing the toxic and side effects of drugs on normal tissues.
- **Prolong blood circulation time**: The blood circulation time of aZIF - 8 in the body is longer, which helps to increase the accumulation of drugs at the tumor site.
- **Increase tumor accumulation**: Compared with traditional ZIF - 8, aZIF - 8 has a higher accumulation in the tumor microenvironment, improving the treatment effect.
- **Reduce lung accumulation**: The accumulation of aZIF - 8 in the lungs is significantly reduced, reducing potential adverse reactions.

Through these improvements, as a new type of nano - system, aZIF - 8 shows better biocompatibility, longer blood circulation time and higher tumor treatment effect in vivo, especially showing significant advantages in the treatment of esophageal squamous cell carcinoma (ESCC).